Eisai Europe Ltd.
HATFIELD, England, June 1, 2011 - Preliminary results of a Phase II study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's E7080 (lenvatinib [USAN]) demonstrated an Objective Response Rate (ORR) of 59% (34/58, 95% CI:45 - 71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). These results will be presented during an ASCO oral session on June 6, 2011.
HATFIELD, England, January 21, 2011 - The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), today gave a positive opinion for the use of Eisai Europe, Ltd.'s Halaven as a monotherapy indicated in the treatment of patients with locally advanced (LA) or metastatic breast cancer (MBC) who have progressed after at least two chemotherapeutic regimens for advanced disease.
MILAN, October 10, 2010 - Further results from the Phase III EMBRACE study presented today at the European Society of Medical Oncology (ESMO) congress showed that Eisai's eribulin mesylate maintained an overall survival (OS) benefit compared with Treatment of Physician's Choice (TPC) in metastatic breast cancer (MBC) patients, irrespective of their tumour hormone receptor status, extent of disease or prior therapy. Additional analyses of the EMBRACE study (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus Eribulin E7389) investigated the primary endpoint of OS benefit of eribulin versus TPC within several pre-specified sub-groups, including: hormone receptor expression status, number of organs involved, sites of disease and prior treatment with capecitabine.
HATFIELD, England, August 24, 2010 - Eisai today announced the results of a Phase III study for the investigational compound perampanel (E2007), a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered by Eisai and under development for adjunctive treatment of partial seizures in patients with epilepsy.